Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients (SPARTAN)

2. februar 2015 opdateret af: Bristol-Myers Squibb

An Open-Label, Randomized Study Evaluating a Switch From a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors Regimen Plus Any Third Agent to Either a Regimen of Atazanavir/Ritonavir Once Daily and Raltegravir Twice Daily or to a Regimen of Atazanavir/Ritonavir Once Daily and Tenofovir/Emtricitabine Once Daily in Virologically Suppressed HIV-1 Infected Subjects With Safety and/or Tolerability Issues on Their Present Treatment Regimen.

The purpose of this study is to determine whether HIV-1-infected patients, who are virologically suppressed on a regimen of 2 nucleoside reverse transcriptase inhibitors plus any third agent but are experiencing safety and/or tolerability issues, will maintain virologic suppression after switching to a regimen of heat-stable ritonavir boosted atazanavir, 300/100 mg, once daily plus raltegravir, 400 mg, twice daily.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Allocation: Randomized nonstratified

Intervention model: Parallel versus comparator

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

132

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Det Forenede Kongerige
      • Brighton, Det Forenede Kongerige, BN2 1ES
        • Local Institution
      • London, Det Forenede Kongerige, E9 6SR
        • Local Institution
      • London, Det Forenede Kongerige, NW3 2QG
        • Local Institution
      • Sheffield, Det Forenede Kongerige, S10 2RX
        • Local Institution
    • Greater London
      • London, Greater London, Det Forenede Kongerige, SW10 9EL
        • Local Institution
    • Greater Manchester
      • Manchester, Greater Manchester, Det Forenede Kongerige, M8 5RB
        • Local Institution
  • Forenede Stater
    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72207
        • Health For Life Clinic Pllc
    • California
      • Palm Springs, California, Forenede Stater, 92264
        • Eisenhower Medical Center
      • San Francisco, California, Forenede Stater, 94109
        • Metropolis Medical Pc
    • Florida
      • Daytona Beach, Florida, Forenede Stater, 32117
        • Consultive Medicine
      • Orlando, Florida, Forenede Stater, 32805
        • Orange County Health Dept.
      • West Palm Beach, Florida, Forenede Stater, 33401
        • Triple O Medical Services, P.A.
    • Massachusetts
      • Springfield, Massachusetts, Forenede Stater, 01105
        • The Research Institute
    • New York
      • Rochester, New York, Forenede Stater, 14607
        • Aids Care
  • Frankrig
      • Lyons Cedex 04, Frankrig, 69317
        • Local Institution
      • Orleans Cedex 2, Frankrig, 45067
        • Local Institution
      • Paris, Frankrig, 75020
        • Local Institution
      • Paris Cedex 14, Frankrig, 75679
        • Local Institution
      • Strasbourg Cedex, Frankrig, 67091
        • Local Institution
    • Cedex 12
      • Paris, Cedex 12, Frankrig, 75551
        • Local Institution
  • Italien
      • Genova, Italien, 16128
        • Local Institution
      • Genova, Italien, 16132
        • Local Institution
      • Milano, Italien, 20127
        • Local Institution
      • Milano, Italien, 20142
        • Local Institution
      • Roma, Italien, 00149
        • Local Institution
  • Polen
      • Warszawa, Polen, 01-201
        • Local Institution
      • Wroclaw, Polen, 50-136
        • Local Institution
  • Spanien
      • Alicante, Spanien, 03010
        • Local Institution
      • Barcelona, Spanien, 08036
        • Local Institution
      • Madrid, Spanien, 28006
        • Local Institution
      • Madrid, Spanien, 28007
        • Local Institution
      • Madrid, Spanien, 28046
        • Local Institution
      • Madrid, Spanien, 28805
        • Local Institution
  • Tyskland
      • Bochum, Tyskland, 44791
        • Local Institution
      • Frankfurt, Tyskland, 60590
        • Local Institution
      • Frankfurt Am Main, Tyskland, 60311
        • Local Institution
      • Hamburg, Tyskland, 20246
        • Local Institution
      • Munich, Tyskland, 80336
        • Local Institution

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria

  • Current treatment regimen of 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus any third agent for at least 3 months immediately prior to screening
  • Virologic suppression (HIV-1 RNA <50 c/mL) for at least 3 months immediately prior to screening
  • Virologic suppression (HIV-1 RNA <40 c/mL) using the Abbott m2000rt® polymerase chain reaction assay during screening period
  • Treatment-related safety and/or tolerability issues to a regimen consisting of 2 NRTIs plus any third agent

Key Exclusion Criteria

  • History of switch in highly active antiretroviral therapy due to virologic failure
  • History of genotypic resistance to any component of the study regimen (atazanavir, raltegravir, tenofovir/emtricitabine)
  • History of exposure to atazanavir/ritonavir or raltegravir prior to entering the study
  • Experiencing safety and/or tolerability issues to tenofovir/emtricitabine or raltegravir
  • Switch of any component of HIV antiretroviral medication regimen in the last 3 months immediately prior to or during the screening period

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Atazanavir/Ritonavir + Raltegravir
Atazanavir + Ritonavir (heat-stable) + Raltegravir
Medicin: Atazanavir
Capsules, Oral, 300mg, Once daily, 48 weeks
Andre navne:
  • Reyataz
Medicin: Ritonavir (heat-stable)
Tablets, Oral, 100 mg, Once daily, 48 weeks
Andre navne:
  • Norvir
Medicin: Raltegravir
Tablets, Oral, 400 mg, Twice daily, 48 weeks
Andre navne:
  • Isentress
Andet: Atazanavir/Ritonavir + Tenofovir/Emtricitabine

Reference

Atazanavir + Ritonavir (heat-stable) + Tenofovir/Emtricitabine
Medicin: Atazanavir
Capsules, Oral, 300mg, Once daily, 48 weeks
Andre navne:
  • Reyataz
Medicin: Ritonavir (heat-stable)
Tablets, Oral, 100 mg, Once daily, 48 weeks
Andre navne:
  • Norvir
Medicin: Tenofovir/Emtricitabine
Tablets, Oral, 300/200 mg, Once daily, 48 weeks
Andre navne:
  • Truvada

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants With HIV-1 RNA Level <40 c/mL at Week 24
Tidsramme: From Day 1 to Week 24
HIV-1 RNA level was measured with the Abbott m2000rt® polymerase chain reaction assay. Response rates were assessed using an intent-to-treat algorithm, with numerator representing patients meeting the response criteria, and denominator representing all randomized patients. Randomized patients not meeting the criteria for treatment failure (eg, discontinuation of study therapy or virologic rebound at or before Week 24) were considered responders. Virologic rebound was defined as 2 consecutive on-treatment HIV-1 RNA levels ≥40 c/mL or the last on-treatment HIV-1 RNA level ≥40 c/mL followed by discontinuation. Patients who experienced treatment failure or had missing Week 24 HIV-1 RNA levels were considered failures. RNA=ribonucleic acid; HIV=human immunodeficiency virus.
From Day 1 to Week 24

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants With HIV-1 RNA Level <40 c/mL at Week 48
Tidsramme: From Day 1 to Week 48
Percentages of patients with HIV-1 RNA levels <40 c/mL were summarized at each scheduled visit. Longitudinal plots were created to display proportion versus visit week through Weeks 24 and 48 with error bars representing 95% confidence intervals.
From Day 1 to Week 48
Number of Participants With Virologic Rebound at Weeks 24 and 48
Tidsramme: Day 1 to Weeks 28 and 48
Viral genotypic and phenotypic resistance profiles were assessed for virologic rebound (HIV-1 RNA level ≥40 c/mL). Only patients with HIV-1 RNA levels ≥500 c/mL met the criteria for resistance testing. Genotypic substitutions at baseline were summarized for virologic rebound. The genotypic resistance profile presented patients with genotypable isolates, those with protease inhibitor substitutions from genotypable isolates, those with integrase substitutions from genotypable isolates, and those with selected reverse transcriptase substitutions from genotypable isolates using the most current version of the International AIDS Society-USA list and Stanford HIV Drug Resistance Database. Newly emergent genotypic substitutions were summarized analogously for virologic rebound without baseline phenotypic resistance to atazanavir, ritonavir, or raltegravir, using all on-treatment isolates.
Day 1 to Weeks 28 and 48
Number of Participants With Genotypable/Phenotypable Isolates, Emergent Genotypic Substitutions in Patients With Genotypable Isolates, and Phenotypic Resistance in Patients With Phenotypable Isolates at Week 24
Tidsramme: Day 1 to Week 24
Viral genotypic and phenotypic resistance profiles were assessed for virologic rebound (HIV-1 RNA level ≥40 c/mL). Only patients with HIV-1 RNA levels ≥500 c/mL met the criteria for resistance testing. Genotypic substitutions at baseline were summarized for virologic rebound. The genotypic resistance profile presented patients with genotypable isolates, those with protease inhibitor substitutions from genotypable isolates, those with integrase substitutions from genotypable isolates, and those with selected reverse transcriptase substitutions from genotypable isolates using the most current version of the International AIDS Society-USA list and Stanford HIV Drug Resistance Database. Newly emergent genotypic substitutions were summarized analogously for virologic rebound without baseline phenotypic resistance to atazanavir, ritonavir, or raltegravir, using all on-treatment isolates. pts=patients
Day 1 to Week 24
Number of Participants With Genotypable/Phenotypable Isolates, Emergent Genotypic Substitutions in Patients With Genotypable Isolates, and Phenotypic Resistance in Patients With Phenotypable Isolates at Week 48
Tidsramme: Day 1 to Week 48
Viral genotypic and phenotypic resistance profiles were assessed for virologic rebound (HIV-1 RNA level ≥40 c/mL). Only patients with HIV-1 RNA levels ≥500 c/mL met the criteria for resistance testing. Genotypic substitutions at baseline were summarized for virologic rebound. The genotypic resistance profile presented patients with genotypable isolates, those with protease inhibitor substitutions from genotypable isolates, those with integrase substitutions from genotypable isolates, and those with selected reverse transcriptase substitutions from genotypable isolates using the most current version of the International AIDS Society-USA list and Stanford HIV Drug Resistance Database. Newly emergent genotypic substitutions were summarized analogously for virologic rebound without baseline phenotypic resistance to atazanavir, ritonavir, or raltegravir, using all on-treatment isolates. pts=patients
Day 1 to Week 48
Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, Treatment-emergent Adverse Events (AEs) Leading to Discontinuation, and Treatment-emergent AEs
Tidsramme: Day 1 to Week 48
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug.
Day 1 to Week 48
Mean Changes in Fasting Lipid Levels From Baseline to Week 48
Tidsramme: From Baseline to Week 48
LD=low-density lipoprotein; HDL=high-density lipoprotein.
From Baseline to Week 48

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Bristol-Myers Squibb

Efterforskere

  • Studieleder: Bristol-Mayers Squibb, Bristol-Mayers Squibb

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. oktober 2011

Primær færdiggørelse (Faktiske)

1. september 2013

Studieafslutning (Faktiske)

1. februar 2014

Datoer for studieregistrering

Først indsendt

7. april 2011

Først indsendt, der opfyldte QC-kriterier

8. april 2011

Først opslået (Skøn)

11. april 2011

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

19. februar 2015

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. februar 2015

Sidst verificeret

1. februar 2015

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • AI424-402
  • 2009-017032-41 (EudraCT nummer)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med HIV, Combination Therapy

Kliniske forsøg med Atazanavir

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Mauritania

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner